Book Offers Timely Insights On IP, Drugs And Public Health In Developing Countries 25/04/2012 by Intellectual Property Watch Leave a Comment IP-Watch is a non-profit independent news service, and subscribing to our service helps support our goals of bringing more transparency to global IP and innovation policies. To access all of our content, please subscribe now. You also have the opportunity to offer additional support to your subscription, or to donate. A recent book comes in time for the international policy debates coming to a head over access to medicines, intellectual property rights and public health in developing countries. Intellectual Property, Pharmaceuticals and Public Health: Access to Drugs in Developing Countries contains chapters by a wide range of scholars and experts looking at national strategies for pharmaceutical development and the protection of public health in the context of globalisation of trade and production, and harmonisation of IP laws. Chapters provide a reference on key issues and developments in Bangladesh, Brazil, Canada, China, Colombia, Mexico, Morocco, South Africa, and Thailand that form the core of global policy debates in recent years. The book is considered to offer “much-needed” empirical evidence on issues surrounding changing regulatory frameworks and research and development structures. Available here from Edward Elgar, the book was edited by Kenneth Shadlen of the London School of Economics and Political Science; Samira Guennif of the Université Paris 13; Alenka Guzmán of the Autonomous Metropolitan University-Iztapalapa, Mexico; and N. Lalitha of the Gujarat Institute of Development Research, India. "Book Offers Timely Insights On IP, Drugs And Public Health In Developing Countries" by Intellectual Property Watch is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.